Update information
October 2018: The recommendations and section 2 were updated because the marketing authorisation for eltrombopag now includes people who have not had a splenectomy.
April 2017: The company changed from GlaxoSmithKline to Novartis. Contact details for the patient access scheme updated.
Minor changes since publication
January 2023: The title of this guidance was updated and the term 'immune (idiopathic) thrombocytopenic purpura' was changed to 'immune thrombocytopenia' throughout.
ISBN 978-1-4731-0236-1